An Open-label, Multicenter, Randomized Phase 3 Study of First-line Encorafenib Plus Cetuximab With or Without Chemotherapy Versus Standard of Care Therapy with A Safety Lead-in of Encorafenib And Cetuximab Plus Chemotherapy in Participants with Metastatic BRAF V600E-Mutant Colorectal Cancer (NCT04607421)
BREAKWATER
This trial is No longer recruiting
Registration number NCT04607421
Program & service
This trial is being run with the Cancer service, and as part of the Medical Oncology program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Ben Markman
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR